Pliant Therapeutics PLRX Stock Price Today

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.

PLRX shares were trading at $28.29 per share on Friday afternoon, up $0.29 (+1.04%). Year-to-date, PLRX has gained 46.35%, versus a 8.91% rise in the benchmark S&P 500 index during the same period. The stock has plummeted 52.9% over the past six months and 76.9% over the past year to close its last trading session at $4.19.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Hence, it could be wise to avoid struggling stocks Pliant Therapeutics , Local Bounti , and Kiromic BioPharma . These stocks are F rated in our proprietary rating system. Both price targets represent a 5x multiple vs the current share price of 20 SEK.

Analyst Ratings

Its net loss widened by 35.7% from the year-ago value to $34.73 million, resulting in a loss per share of $64.42. Moreover, as of December 31, 2022, the company’s total liabilities stood at $17.74 million, compared to $3.41 million as of December 31, 2021. 1.1% in the first quarter of 2023, falling short of estimates. This is a significant pullback from the 2.6% growth in the fourth quarter and a 3.2% increase in the third quarter of 2022. PLRX – The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year.

However, having looked a bit closer at it, we conclude that Pliant’s 12-week data is inconclusive and with that we see a significant risk going forward…. Pliant Therapeutics Inc. upsized its planned initial public offering on Tuesday, saying in a regulatory filing that it plans to offer 9 million shares, up from an earlier 6 million. Represents the company’s profit divided by the outstanding shares of its common stock. There may be delays, omissions, or inaccuracies in the Information. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.

PLRX Pliant Therapeutics, Inc.Stock Price & Overview

Additionally, the company’s net loss and loss per share worsened by 98% and 19.8% year-over-year to $111.07 million and $1.27, respectively. Pliant and Vicore are both focused on one IPF drug, and both are in a broadly similar stage of testing. Despite that, Pliant is trading at a 12 times higher valuation than Pliant. There are three completed studies on drugs on the market. As 80% of Pliant´s placebo clients were treated on Standard of Care, Pliant´s placebo sample clients should show a smaller deterioration than placebo clients from the three samples. The data looks positive at first glance as the placebo group looks to perform worse than treatment groups.

I want to stress that the data may be too inconclusive to conclude that the drug is not actually doing something good. Pliant reminds us of Belgian biotech Galapagos N.V., which first posted promising 12-week data but later had to terminate the program, losing over USD 3 bn in market capitalization. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

Private Companies

PLRX’s weak fundamentals are reflected in its POWR Ratings. It has an overall F rating, equating to a Strong Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree. PLRX has lost 19.7% over the past three months to close the last trading session at $28.00. Against this backdrop, it could be wise to steer clear of stocks PLRX, LOCL, and KRBP, with bleak fundamentals and poor outlooks. It is the first IPF drug that turns a deadly disease into a survivable one.

• As of this writing, more than 37 million shares of the stock have changed hands.
• After week 18, you see a material improvement in lung function.
• The current clinical trial was going over the safety and efficacy of treating these patients with the drug.
• Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

Analysts expect PLRX to report a loss per share of $2.76 for the fiscal year ending December 2023. The company’s revenue for the ongoing year is expected to decline 65.6% year-over-year to $3.33 million. Moreover, the company missed the consensus EPS estimates in three of the trailing four quarters. Its flagship product candidate is bexotegrast (PLN-74809), an oral small-molecule, a dual-selective inhibitor of avß6 and avB1. There are two drugs on the market which sold more than USD 3.5 billion in 2021.

The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum.

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Both drugs have incomparable results in comparison with Vicore. The USD 3.5 billion price tag represents a 35x multiple from the current share price. The technique has proven to be very useful for finding positive surprises. According to Pliant Therapeutics, results from the clinical trial were positive. This saw PLN succeed in meeting its primary and secondary endpoints in the clinical trial. That includes being well-tolerated over a 12-week period and showing a favorable pharmacokinetic profile.

The fact that Vicore chose to announce the results there indicates that they are very bullish on the readout. You would not want to publish results in the most important event unless you have high confidence you can impress the industry. Not only does it give us confidence in the next readout, but it will also put Vicore on the screens of US investors.

Pliant Therapeutics Inc.

We believe it may be very symbolic for Pliant´s data readout. Bloomberg Wealth with David Rubenstein Renowned financier, Co-Founder of The Carlyle Group, and philanthropist David Rubenstein provides unparalleled access to the world’s most successful investors. In one-on-one interviews, Rubenstein will learn investing strategies and tactics from some of the world’s top wealth creators. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

The fact it is off the radar screens of US investors creates a great opportunity. The May 21 presentation at the most important IPF event could be a game-changing moment for Vicore. Pliant compares the results of its medication with the results of its placebo clients.

Pliant´s sample of placebo clients is not really placebo – 80% of the placebo clients were treated on Standard of Care . “Be strategic when disclosing data” quote could be taken in several ways. In my view, it is quite a strange quote from a pharma CEO.

Dividends

A valuation method that multiplies the https://1investing.in/ of a company’s stock by the total number of outstanding shares. Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1…. KRBP’s loss from operations worsened by 20.9% year-over-year to $31.11 million for the fiscal year that ended December 31, 2022.

PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibro… Shares of Pliant Therapeutics have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients. A reverse stock split is often seen as a red flag for investors, indicating that a company is struggling and trying to boost its stock price artificially. KRBP’s decision to do so to meet Nasdaq’s minimum bid price requirement suggests a struggle to maintain its listing status. LOCL’s loss from operations worsened by 111.4% year-over-year to $94.53 million for the fiscal year that ended December 31, 2022. Its adjusted EBITDA loss widened 67.4% from the prior year to $29.78 million.

To access LOCL’s ratings for Value, Stability, Sentiment, and Growth. To see the other ratings of PLRX for Growth, Sentiment, and Momentum. The unexpectedly steep slowdown in economic growth in the first quarter of 2023 suggests the economy is feeling the brunt of persistently high inflation and rising interest rates.

Real-what happens if i do not pay my unsecured debt last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Pliant Therapeutics Inc. shares soared 55% in their trading debut Wednesday, after the company’s initial public offering priced at $16 a share, the high end of its $14 to $16 range. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

• LOCL’s forward Price/Sales of 1.52x is 31% higher than the industry average of 1.16x.
• If that understanding is right, then it is quite a worrying sign.
• I/we have a beneficial short position in the shares of PLRX either through stock ownership, options, or other derivatives.
• Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

We are short Pliant through long maturity deep out-of-the-money put options. The Pliant share price has been rising sharply despite rumours of another capital raise. In my view, there is a significant downside risk in the stock price.

As mentioned above, Pliant´s trading at 12 times higher valuation vs a drug with much stronger results does not make sense. At 36 weeks of treatment with C21, shows an FVC increase (+633). My understanding of Pliant´s placebo clients shows the opposite.